The constant evolution of Hematopoietic Cell Transplantation (HCT) and cellular therapies requires the continuous development and improvement of information technology (IT) tools and features, as a prerequisite to adjust to new and innovative treatments and associated legal and technical requirements. In order to answer the current and future needs of the HCT stakeholders –Professionals and Competent Authorities (CA) – the EBMT Registry requires a significant update of its structure and features.
The proposed development will enable the correct monitoring of HCT activities, patient and donor safety oversight, and recording/collecting quality, safety, and efficacy data. A new EBMT registry will be built based on the needs identified by HCT professionals and CA and aims to be as flexible as possible, allowing its customization at regional/federal levels to serve and adapt to different realities, in a user-friendly manner.
The future platform aims to provide an adequate answer to the requirements of clinicians/professionals involved in HCT and Cellular Therapies on one hand and other stakeholders such as CA or other health authorities on the other while complying with best practices associated with standardization and data protection (General Data Protection Regulation - GDPR), ultimately enabling better health decisions leading to improved, outcomes and care for EU.
